Semaglutide, found in Ozempic and Wegovy, may lower dementia risk in diabetics, with stronger effects in older adults and women. The findings are based on data from nearly 1.7 million people.

An analysis of 1.7 million patients shows semaglutide may significantly reduce Alzheimer and vascular dementia risk compared with other diabetes drugs.

CHICAGO — The combination of IV bimagrumab and subcutaneous semaglutide was linked to large reductions in body weight and fat mass at 72 weeks with no serious impact on lean mass, according ...

A new clinical trial found that taking a popular diabetes and weight-loss drug once weekly significantly improves blood sugar and leads to substantial weight loss in adults with type 1 diabetes ...

While the renal benefits of oral semaglutide vs placebo in the SOUL trial didn't match the effects seen with the injectable formulation in the FLOW trial, the observed trends suggest improvements.

A combination treatment of semaglutide, trevogrumad and garetosmab causes fat loss and muscle growth in primate trials. Full trial results for humans are expected later in 2025. Results from the Phase ...

New research compared the effect of semaglutide vs. tirzepatide on weight loss over a 72 week period. Here's what the study found, and what a doctor has to say about it.

GLP-1 receptor agonist semaglutide significantly outperformed placebo in an ongoing phase 3 trial, showing reductions in steatohepatitis and liver fibrosis, in addition to cardiometabolic benefits.

CHICAGO -- Semaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time building its positions in peripheral artery disease (PAD) and with an oral ...

Semaglutide, available under the brand names Ozempic and Wegovy, may help decrease the risk of major adverse cardiovascular events after just six months of starting the medication, a new study ...

MALAGA, Spain—Clinicians caring for patients with obesity or overweight and established cardiovascular disease should start patients on semaglutide (Wegovy; Novo Nordisk) as soon as possible. That’s ...

A weekly dose of semaglutide, a drug used to manage diabetes and weight loss, was effective in 63% of patients at treating a serious form of fatty liver disease, a new study has found.